Abstract:When ML-1 human myeloid leukemia cells are exposed to DNA damaging agents, they exhibit dramatic changes in the expression of a variety of gene products. This includes an increase in p53 (wild-type), a decrease in BCL2, a p53-dependent increase in the BCL2 family member BAX, and increases in Growth Arrest and DNA Damage-inducible (GADD) genes such as GADD45; these changes occur as early events in a sequence that culminates in DNA damage-induced apoptosis. DNA damaging agents have now been tested for effects on expression of another BCL2 family member, MCL1, a gene expressed during ML-1 cell differentiation. Expression of MCL1 was found to increase upon exposure of ML-1 cells to various types of DNA damaging agents, including ionizing radiation, ultraviolet radiation, and alkylating drugs. The increase in MCL1 occurred rapidly and was transient, levels of the MCL1 mRNA being elevated within 4 h and having returned to near baseline within 24 h. An increase in the Mcl1 protein was also seen, with the maximal increase occurring at an intermediate dose of IR (5 Gray) and lesser increases occurring at either lower or higher doses. The increase in expression of MCL1 was further studied using a panel of human cell lines that includes cells containing or not containing alterations in p53 as well as cells sensitive or insensitive to the apoptosis-inducing effects of DNA damage. The DNA damage-induced increase in MCL1 mRNA did not depend upon p53 as it was seen in cells lacking functional p53. However, the increase did depend upon susceptibility to apoptosis as it was not seen in cells insensitive to apoptosis-induction by DNA damaging agents. These findings demonstrate that cytotoxic DNA damage causes an increase in the expression of MCL1 along with increases in GADD45 and BAX and a decrease in BCL2. Furthermore, while the increase in GADD45 is seen both in cells that undergo growth arrest and in cells that undergo apoptosis in response to DNA damage, alterations in the profile of expression of BCL2 family members occur exclusively in cells that undergo the apoptotic response, with some family members increasing through p53-dependent (BAX) and others through p53-independent (MCL1) pathways. Overall, expression MCL1 can increase during the induction of cell death as well as during the induction of differentiation.

Mcl-1 Mediates Cytokine Deprivation Induced Apoptosis of Human Myeloma Cell Line XG-7.

IL-6 Inhibits Apoptosis of Human Myeloma Cell Line XG-7 Through Activation of JAK/STAT Pathway and Up-Regulation of Mcl-1.

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

Interleukin (IL)‐7 Promotes T‐cell Survival by Stabilization of Mcl‐1

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

Different Bcl-2 family members participates dexamethasone-induced apoptosis of different human myeloma cell lines

Roles of Phosphorylated P210bcr/abl and Hsp90 Protein in Apoptosis Induced by Berbamine in K562 Cells.

Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.

Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3 Beta Activity and Associates with Poor Prognosis in Human Breast Cancer

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy

Induction of BCL2 Family Member MCL1 As an Early Response to DNA Damage

4-Chlorobenzoyl Berbamine, a Novel Berbamine Derivative, Induces Apoptosis in Multiple Myeloma Cells Through the IL-6 Signal Transduction Pathway and Increases FOXO3a-Bim Expression.

Physiological Functions of Mcl-1: Insights From Genetic Mouse Models

Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells

Bcl-xL is Associated with the Anti-Apoptotic Effect of IL-15 on the Survival of CD56(dim) Natural Killer Cells.

Activation by CD40 Ligand Shifts Bcl-2 Family Protein Expression from Death-by-Default to Survival-by-Default.

Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells

Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy

Regulation of Bcl-Xl Expression and Fas Susceptibility in Mouse B Cells by CD40 Ligation, Surface IgM Crosslinking and IL-4.

BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation